📚 ESC 2025 Coverage: Expanding the Benefit Zone: Can β Blockers Help Post-MI Patients with Mildly Reduced Ejection Fraction? by Dr. Yahyavi, Cardiovascular Researcher.

📚 ESC 2025 Coverage: The SMuRF-less Illusion: Inflammation Unmasks Hidden Cardiovascular Risk in Healthy Women, by Dr. Hafezi, Cardiovascular Specialist.

📚 ESC 2025 Coverage: A Classic Revived: Digitoxin Lowers Risk in HFrEF When Added to Modern Therapy, by Dr. Talasaz, Clinical Pharmacist.

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

📚 ESC 2025 Coverage: All at Once or One Step at a Time? Immediate Revascularisation Falls Short of Non-Inferiority in STEMI Patients, by Dr. Soltani Moghadam, Cardiovascular Researcher.

📚 ESC 2025 Coverage: Finding the Silent Beat: Remote ECG Screening Slightly Boosts Atrial Fibrillation Detection, by Dr. Tahmtan, Fellowship of Electrophysiology.

📚 ESC 2025 Coverage: Cholesterol Crushed, But Grafts Still Failed: Evolocumab Misses the Mark in NEWTON-CABG, by Dr. Ghavidel, Cardiovascular Surgeon.

📚 ESC 2025 Coverage: Cholesterol Crushed, But Grafts Still Failed: Evolocumab Misses the Mark in NEWTON-CABG, by Dr. Ghavidel, Cardiovascular Surgeon.

📚 ESC 2025 Coverage: More Isn’t Always Better: Dual Antiplatelet Therapy Falls Short After CABG for ACS, by Dr. Mehrpouya, Interventional Cardiologist.

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum

VICTORIA and VICTOR Clinical Trials

📚 ESC 2025 Coverage: Bridging Stability and Severity: Vericiguat’s Role Expands in Heart Failure Therapy, by Dr. Taghavi, Fellowship of Heart Failure.